11/14/2022 0 Comments Localized weather mod![]() ![]() Our focus is now to timely complete the recruitment of UC patients into the two induction studies for which the top-line results are expected for the end of 2024. ![]() Ehrlich, M.D., CEO of Abivax, added: "We are very happy that our pivotal global phase 3 program has successfully started in the US with the enrollment of the first patient. ![]() I am optimistic that the ABTECT program will confirm obefazimod's potential to address these medical needs." As a practicing gastroenterologist, I am confronted every day with the high unmet medical need for safe therapies that have long-term efficacy and convenient administration for patients with ulcerative colitis. Obefazimod has already shown very promising results in the precedent phase 2a and phase 2b induction and maintenance trials. US investigators are highly motivated to recruit patients into the two initial induction studies. Janowitz Division of Gastroenterology at Mount Sinai, New York, NY, and principal investigator of the studies in the US, said : "As the principal investigator in the US, I am excited about the first patient included in the obefazimod phase 3 program for the treatment of moderate to severe UC. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai Chief of the Henry D. ![]() PARIS, FRANCE / ACCESSWIRE / Octo/ Abivax SA (Euronext Paris: FR0012333284 - ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today that the first patient has been enrolled in the US into its global phase 3 clinical program ("ABTECT program") with product candidate obefazimod for the treatment of moderate to severe ulcerative colitis (UC). Program is progressing according to plan and top-line results of the two induction studies are expected to become available end of 2024 Obefazimod 25mg and 50mg doses will be investigated in advanced therapies naïve and in advanced therapies failure patients First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the USġ,200 UC patients across 36 countries and 600 study centers will take part in the ABTECT program which consists of two induction studies and a single subsequent maintenance study ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |